Deblina Rababi

Deblina Rababi

25 Jun, 2025

Deblina Rababi is an experienced regulatory professional specializing in medical device compliance under EU MDR. She has expertise in authoring and reviewing Clinical Evaluation Reports (CER), Clinical Evaluation Plans (CEP), Literature Search Reports (LSR), Periodic Safety Update Reports (PSUR), Post-Market Surveillance Reports (PMSR), and Post-Market Clinical Follow-up (PMCF) documentation.

As an Associate Manager at Celegence, she ensures the development of high-quality regulatory submissions, supporting medical device manufacturers in achieving compliance. Her detail-oriented approach and regulatory expertise contribute to streamlined documentation and successful audits.

Other Related Articles

Beyond Document Delivery: How a Compliance-First CER Strategy Helped Achieve a Successful Notified Body Review

Blog Medical Devices

Beyond Document Delivery: How a Compliance-First CER Strategy Helped Achieve a Successful Notified Body Review

22 Jul, 2026

Responsible Integration of Artificial Intelligence in Clinical Evaluation Reports

Blog Medical Devices

Responsible Integration of Artificial Intelligence in Clinical Evaluation Reports

21 Jul, 2026

Navigating the Nagoya Protocol in Pharmaceutical Regulatory Affairs

Blog Pharmaceutical

Navigating the Nagoya Protocol in Pharmaceutical Regulatory Affairs

15 Jul, 2026

Companion Diagnostic Studies Under IVDR: Regulatory Requirements, Study Design, and Clinical Evidence Generation

Blog Medical Devices

Companion Diagnostic Studies Under IVDR: Regulatory Requirements, Study Design, and Clinical Evidence Generation

08 Jul, 2026

Beyond “Inactive”: Mastering Type IV DMFs for Excipients Using IPEC Guidance

Blog Pharmaceutical

Beyond “Inactive”: Mastering Type IV DMFs for Excipients Using IPEC Guidance

02 Jul, 2026

Ethylene Oxide in Pharmaceuticals and Consumer products – Essential Intermediate, High-Risk Exposure – A Regulatory Deep Dive

Blog Pharmaceutical

Ethylene Oxide in Pharmaceuticals and Consumer products – Essential Intermediate, High-Risk Exposure – A Regulatory Deep Dive

26 Jun, 2026

How to Address Data Consistency Challenges in EU MDR Submissions: A CAPTIS® Perspective

Blog Medical Devices

How to Address Data Consistency Challenges in EU MDR Submissions: A CAPTIS® Perspective

17 Jun, 2026

From Supplier to Label: Mastering Allergen Statements in Drugs and Cosmetics

Blog Pharmaceutical

From Supplier to Label: Mastering Allergen Statements in Drugs and Cosmetics

05 Jun, 2026

View All